Can AnaptysBio, Inc. (ANAB)’s Tomorrow Be Different? The Stock Increases Again

December 7, 2017 - By Adrian Mccoy

The stock of AnaptysBio, Inc. (NASDAQ:ANAB) is a huge mover today! The stock increased 8.00% or $6.56 during the last trading session, reaching $88.51. About 484,254 shares traded or 8.37% up from the average. AnaptysBio, Inc. (NASDAQ:ANAB) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $2.08B company. It was reported on Dec, 7 by Barchart.com. We have $92.94 PT which if reached, will make NASDAQ:ANAB worth $104.00M more.

Analysts await AnaptysBio, Inc. (NASDAQ:ANAB) to report earnings on February, 6. After $-0.45 actual earnings per share reported by AnaptysBio, Inc. for the previous quarter, Wall Street now forecasts -6.67 % EPS growth.

More recent AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: Globenewswire.com which released: “AnaptysBio Files Registration Statement for Proposed Public Offering” on October 10, 2017. Also Globenewswire.com published the news titled: “AnaptysBio to Participate in Upcoming Investor Conferences” on October 31, 2017. Fool.com‘s news article titled: “Here’s Why AnaptysBio Inc. Is Rocketing Higher Today” with publication date: October 10, 2017 was also an interesting one.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.08 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.